Skip to content
Home/Companies/Biotech/Redpin Therapeutics

Redpin Therapeutics

Biotech·US·Exited 2022·Held 2yr
Entry
2020
Hold
2yr
Exit
2022

Who owns Redpin Therapeutics?

Redpin Therapeutics was owned by 4Bio Partners through 4BIO Ventures II (2019 vintage) from 2020 to 2022, exited via Trade Sale.

Buyer identity available on Pro.

Hand-verified · updated 2026-07-16

4Bio Partners
Investor
4Bio Partners
4BIO Ventures II · 2019 · Life Sciences VC

Key facts

HQUS
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
MOIC
–
Exit Year
2022

More from 4BIO Ventures II

Other portfolio companies in the same fund.

Araris Biotech
Araris Biotech
Exited 2025
BiotechSwitzerland· 2020
to

More 4Bio Partners portfolio companies

From the same investor, across funds.

Cytospire Therapeutics
Cytospire Therapeutics
Active
BiotechUK· 2026
Actithera
Actithera
Active
BiotechSwitzerland· 2025
Hornet Therapeutics
Active
BiotechUK· 2024
March Biosciences
March Biosciences
Active
BiotechUS· 2024
Ascend Advanced Therapies
Ascend Advanced Therapies
Active
BiotechUK· 2023
Trogenix
Trogenix
Active
BiotechUK· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Redpin Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Redpin Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue